Modern Pharmaceutics for Cardiovascular Diseases
Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite...
Guardat en:
| Format: | Online |
|---|---|
| Idioma: | anglès |
| Publicat: |
MDPI - Multidisciplinary Digital Publishing Institute
2024
|
| Matèries: | |
| Accés en línia: | ONIX_20240514_9783036599809_49 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
| _version_ | 1869517613776764928 |
|---|---|
| collection | Directory of Open Access Books |
| description | Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases. The present reprint brings together original and review articles aiming to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years. |
| format | Online |
| id | doab-20.500.12854ir-137447 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2024 |
| publishDateRange | 2024 |
| publishDateSort | 2024 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-1374472024-05-14T13:07:13Z Modern Pharmaceutics for Cardiovascular Diseases Tudorancea, Ionut Iliescu, Radu aspirin coronary artery disease prevention gastric protection micronization collagen cogrinding arterial hypertension HTN nuclear factor erythroid factor 2-related factor 2 Nrf2 oxidative stress antioxidant atherosclerosis pharmacotherapy emergent therapeutics natural anti-atherosclerotic products lipids lipoproteins small dense LDL cholesterol prevention therapy inflammation colchicine NLRP3 inflammasome coronary artery disease acute coronary syndrome heart failure contractility calcium cardiomyocyte myofilament HDAC inhibitor antifibrotic strategies cardiac fibrosis cardiovascular diseases fibrosis pathways therapeutic strategies regenerative medicine cell-free secretomes paracrine factors single-cell RNA sequencing serine protease inhibitor endothelial barrier renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 angiotensin 1-7 Ang (1-7) COVID-19 long-term effects angiotensin receptor–neprilysin inhibitor sodium-glucose co-transporter-2 inhibitors soluble guanylate cyclase activator cardiac myosin activation autonomic modulation SGLT2i empagliflozin NHE1 NHE11 sodium channel thema EDItEUR::M Medicine and Nursing Although various non-pharmaceutical strategies addressed to the primary prevention of cardiovascular diseases such as tobacco control policies, reducing the consumption of harmful food, and increasing physical activity still represent a key strategy, often they are not sufficient. Moreover, despite the availability of a plethora of pharmaceutic approaches specifically targeting mechanisms involved in cardiovascular diseases over recent years, the burden of these pathologies has only been marginally alleviated. Therefore, new pharmaceutical and non-pharmaceutical strategies are necessary for both primary and secondary prevention to reduce the burden of cardiovascular diseases. The present reprint brings together original and review articles aiming to highlight the advances in the development of modern pharmaceutics for cardiovascular diseases in recent years. 2024-05-14T13:07:04Z 2024-05-14T13:07:04Z 2024 book ONIX_20240514_9783036599809_49 9783036599809 9783036599793 https://directory.doabooks.org/handle/20.500.12854/137447 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International https://mdpi.com/books/pdfview/book/8601 https://mdpi.com/books/pdfview/book/8601 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-9979-3 10.3390/books978-3-0365-9979-3 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036599809 9783036599793 226 open access |
| spellingShingle | aspirin coronary artery disease prevention gastric protection micronization collagen cogrinding arterial hypertension HTN nuclear factor erythroid factor 2-related factor 2 Nrf2 oxidative stress antioxidant atherosclerosis pharmacotherapy emergent therapeutics natural anti-atherosclerotic products lipids lipoproteins small dense LDL cholesterol prevention therapy inflammation colchicine NLRP3 inflammasome coronary artery disease acute coronary syndrome heart failure contractility calcium cardiomyocyte myofilament HDAC inhibitor antifibrotic strategies cardiac fibrosis cardiovascular diseases fibrosis pathways therapeutic strategies regenerative medicine cell-free secretomes paracrine factors single-cell RNA sequencing serine protease inhibitor endothelial barrier renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 angiotensin 1-7 Ang (1-7) COVID-19 long-term effects angiotensin receptor–neprilysin inhibitor sodium-glucose co-transporter-2 inhibitors soluble guanylate cyclase activator cardiac myosin activation autonomic modulation SGLT2i empagliflozin NHE1 NHE11 sodium channel thema EDItEUR::M Medicine and Nursing Modern Pharmaceutics for Cardiovascular Diseases |
| title | Modern Pharmaceutics for Cardiovascular Diseases |
| title_full | Modern Pharmaceutics for Cardiovascular Diseases |
| title_fullStr | Modern Pharmaceutics for Cardiovascular Diseases |
| title_full_unstemmed | Modern Pharmaceutics for Cardiovascular Diseases |
| title_short | Modern Pharmaceutics for Cardiovascular Diseases |
| title_sort | modern pharmaceutics for cardiovascular diseases |
| topic | aspirin coronary artery disease prevention gastric protection micronization collagen cogrinding arterial hypertension HTN nuclear factor erythroid factor 2-related factor 2 Nrf2 oxidative stress antioxidant atherosclerosis pharmacotherapy emergent therapeutics natural anti-atherosclerotic products lipids lipoproteins small dense LDL cholesterol prevention therapy inflammation colchicine NLRP3 inflammasome coronary artery disease acute coronary syndrome heart failure contractility calcium cardiomyocyte myofilament HDAC inhibitor antifibrotic strategies cardiac fibrosis cardiovascular diseases fibrosis pathways therapeutic strategies regenerative medicine cell-free secretomes paracrine factors single-cell RNA sequencing serine protease inhibitor endothelial barrier renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 angiotensin 1-7 Ang (1-7) COVID-19 long-term effects angiotensin receptor–neprilysin inhibitor sodium-glucose co-transporter-2 inhibitors soluble guanylate cyclase activator cardiac myosin activation autonomic modulation SGLT2i empagliflozin NHE1 NHE11 sodium channel thema EDItEUR::M Medicine and Nursing |
| topic_facet | aspirin coronary artery disease prevention gastric protection micronization collagen cogrinding arterial hypertension HTN nuclear factor erythroid factor 2-related factor 2 Nrf2 oxidative stress antioxidant atherosclerosis pharmacotherapy emergent therapeutics natural anti-atherosclerotic products lipids lipoproteins small dense LDL cholesterol prevention therapy inflammation colchicine NLRP3 inflammasome coronary artery disease acute coronary syndrome heart failure contractility calcium cardiomyocyte myofilament HDAC inhibitor antifibrotic strategies cardiac fibrosis cardiovascular diseases fibrosis pathways therapeutic strategies regenerative medicine cell-free secretomes paracrine factors single-cell RNA sequencing serine protease inhibitor endothelial barrier renin-angiotensin-aldosterone system RAAS angiotensin-converting enzyme-2 ACE2 angiotensin 1-7 Ang (1-7) COVID-19 long-term effects angiotensin receptor–neprilysin inhibitor sodium-glucose co-transporter-2 inhibitors soluble guanylate cyclase activator cardiac myosin activation autonomic modulation SGLT2i empagliflozin NHE1 NHE11 sodium channel thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20240514_9783036599809_49 |